Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Precigen (PGEN)
NASDAQ:PGEN
Holding PGEN?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.13Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: 26.14%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress with PRGN-2012, including promising clinical trial results, regulatory designations, and strategic commercial preparations. However, these advancements were offset by workforce reductions, pausing of other clinical trials, and financial losses, which indicate a focused but challenging path forward.Company Guidance
During the Q2 2024 earnings call for Precigen (PGEN) on August 14, 2024, significant guidance was provided regarding the company's strategic focus and financial outlook. The call highlighted the prioritization of PRGN-2012, a gene therapy aimed at treating Recurrent Respiratory Papillomatosis (RRP), which showed a 51% complete response rate and an 86% reduction in surgeries among patients. The therapy received breakthrough and orphan drug designations from the FDA and EMA, with plans to submit a Biologics License Application (BLA) by the end of 2024 and potential commercialization in 2025. Financially, the company announced an equity issuance netting $31.4 million, providing a runway into early 2025, alongside a workforce reduction of over 20% to streamline operations and focus on PRGN-2012.FDA Breakthrough and Orphan Drug Designations
PRGN-2012 received a breakthrough designation and an accelerated path from the FDA in June 2023, along with orphan drug designation from both the FDA and EMA.
Strong Clinical Trial Results for PRGN-2012
In Phase I and II trials, 51% of patients achieved complete response and 86% exhibited reduced surgeries, marking unprecedented results in the treatment of Recurrent Respiratory Papillomatosis.
Commercial Readiness and Strategic Partnerships
Phil Tennant joined as Chief Commercial Officer, leading efforts towards a potential 2025 launch for PRGN-2012, with preparations for global commercialization.
Successful Equity Issuance
The company raised $31.4 million through equity issuance, extending the financial runway into early 2025, and plans to explore additional financing options.
---
PGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $0.88 | $0.82 | -6.82% |
| Aug 14, 2024 | $1.12 | $1.07 | -4.46% |
| May 14, 2024 | $1.37 | $1.44 | +5.11% |
| Mar 19, 2024 | $1.44 | $1.44 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Precigen (PGEN) report earnings?
Precigen (PGEN) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Precigen (PGEN) earnings time?
Precigen (PGEN) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PGEN EPS forecast?
PGEN EPS forecast for the fiscal quarter 2024 (Q4) is -0.07.
---